Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Feb;16(2):461-8.
doi: 10.1007/s10461-010-9864-z.

Comparison of antiretroviral adherence questions

Karina M Berg  1 , Ira B Wilson, Xuan Li, Julia H Arnsten
Affiliations
Randomized Controlled Trial

Comparison of antiretroviral adherence questions

Karina M Berg et al. AIDS Behav. 2012 Feb.

Abstract

Our objective was to compare antiretroviral adherence questions to better understand concordance between measures. Among 53 methadone maintained HIV-infected drug users, we compared five measures, including two single item measures using qualitative Likert-type responses, one measure of percent adherence, one visual analog scale, and one multi-item measure that averaged responses across antiretrovirals. Responses were termed inconsistent if respondents endorsed the highest adherence level on at least one measure but middle levels on others. We examined ceiling effects, concordance, and correlations with VL. Response distributions differed markedly between measures. A ceiling effect was less pronounced for the single-item measures than for the measure that averaged responses for each antiretroviral: the proportion with 100% adherence varied from 22% (single item measure) to 58% (multi-item measure). Overall agreement between measures ranged from fair to good; 49% of participants had inconsistent responses. Though responses correlated with VL, single-item measures had higher correlations. Future studies should compare single-item questions to objective measures.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Distributions of responses to individual adherence questions
a. Distribution of responses to RATING question b. Distribution of responses to FREQUENCY question (FREQ) c. Distribution of responses to PERCENT question d. Distribution of responses to visual analog scale (VAS) e. Distribution of responses to Community Programs for Clinical Research on AIDS questions (CPCRA)
Figure 1
Figure 1. Distributions of responses to individual adherence questions
a. Distribution of responses to RATING question b. Distribution of responses to FREQUENCY question (FREQ) c. Distribution of responses to PERCENT question d. Distribution of responses to visual analog scale (VAS) e. Distribution of responses to Community Programs for Clinical Research on AIDS questions (CPCRA)
Figure 1
Figure 1. Distributions of responses to individual adherence questions
a. Distribution of responses to RATING question b. Distribution of responses to FREQUENCY question (FREQ) c. Distribution of responses to PERCENT question d. Distribution of responses to visual analog scale (VAS) e. Distribution of responses to Community Programs for Clinical Research on AIDS questions (CPCRA)
Figure 1
Figure 1. Distributions of responses to individual adherence questions
a. Distribution of responses to RATING question b. Distribution of responses to FREQUENCY question (FREQ) c. Distribution of responses to PERCENT question d. Distribution of responses to visual analog scale (VAS) e. Distribution of responses to Community Programs for Clinical Research on AIDS questions (CPCRA)
Figure 1
Figure 1. Distributions of responses to individual adherence questions
a. Distribution of responses to RATING question b. Distribution of responses to FREQUENCY question (FREQ) c. Distribution of responses to PERCENT question d. Distribution of responses to visual analog scale (VAS) e. Distribution of responses to Community Programs for Clinical Research on AIDS questions (CPCRA)
See this image and copyright information in PMC

References

    1. Simoni JM, Kurth AE, Pearson CR, et al. Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management. AIDS and Behavior. 2006;10(3):227–245. - PMC - PubMed
    1. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr. 2005;38(4):445–448. - PubMed
    1. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–1423. - PMC - PubMed
    1. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–366. - PubMed
    1. Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty? Curr HIV/AIDS Rep. 2009;6(4):177–186. - PMC - PubMed

Publication types

MeSH terms